http://repository.usmf.md:80/handle/20.500.12710/32503 2026-06-03T03:17:13Z 2026-06-03T03:17:13Z Sajin, Octavian Țurcanu, Adela Guțu, Veaceslav Iziumov, Nina Blaj, Valentina http://repository.usmf.md:80/handle/20.500.12710/33387 2026-06-02T08:59:31Z 2026-01-01T00:00:00Z

Title: Global seroprevalence of anti-HEV IgG and IgM antibodies among pregnant women: a systematic review and meta-analysis Authors: Sajin, Octavian; Țurcanu, Adela; Guțu, Veaceslav; Iziumov, Nina; Blaj, Valentina Abstract: Introduction. Hepatitis E virus (HEV) represents a significant public health concern during pregnancy, being associated with severe maternal and fetal complications. This meta-analysis aimed to estimate the global seroprevalence of anti-HEV IgG and IgM antibodies among pregnant women. Materials and methods. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. Observational studies were identified in PubMed, Scopus, and Web of Science. Pooled seroprevalence estimates were calculated using a random-effects model. Heterogeneity was assessed using Cochran’s Q and the I2 statistic, while publication bias was evaluated by funnel plots and Egger’s regression test. Results. Thirty studies from diverse geographic regions were included. The pooled global seroprevalence of anti-HEV IgG was 11.76% (95% CI: 9.45–14.54), indicating widespread prior exposure. Anti-HEV IgM seroprevalence, reflecting recent infection, was 1.07% (95% CI: 0.61–1.86). Substantial heterogeneity was observed for both markers (I2 > 95%), reflecting marked regional variability. No statistically significant small-study effects were detected by Egger’s regression (p > 0.05). Conclusions. HEV exposure among pregnant women is common globally, with pronounced regional differences, whereas recent infection appears relatively rare at the global level. These findings highlight the need for region-specific surveillance, improved diagnostic standardization, and targeted preventive strategies to reduce HEV-related risks during pregnancy.; Introducere. Virusul hepatitei E (HEV) reprezintă o problemă importantă de sănătate publică în timpul sarcinii, fiind asociat cu complicații materne și fetale severe. Scopul acestei meta-analize a fost estimarea seroprevalenței globale a anticorpilor anti-HEV IgG și IgM la femeile însărcinate. Materiale și metode. A fost realizată o revizuire sistematică și o meta-analiză conform ghidului PRISMA. Studiile observaționale au fost identificate în PubMed, Scopus și Web of Science. Seroprevalențele combinate au fost calculate utilizând un model cu efecte aleatorii. Heterogenitatea a fost evaluată prin testul Q al lui Cochran și indicele I2 , iar biasul de publicare prin funnel plots și testul Egger. Rezultate. Au fost incluse 30 de studii din regiuni geografice diverse. Seroprevalența globală combinată anti-HEV IgG a fost de 11,76% (IC 95%: 9,45–14,54), indicând o expunere larg răspândită. Seroprevalența anti-HEV IgM a fost de 1,07% (IC 95%: 0,61–1,86). Heterogenitatea a fost foarte ridicată pentru ambii markeri (I2 > 95%). Nu a fost identificat un bias de publicare semnificativ. Concluzii. Expunerea la VHE în rândul femeilor însărcinate este frecventă la nivel global, cu variații regionale importante, în timp ce infecția recentă este relativ rară. Rezultatele subliniază necesitatea unor strategii de supraveghere și prevenție adaptate contextului regional.

2026-01-01T00:00:00Z Rahmaddian, Tosi Huvaid, Sevilla Ukhtil Hidayat, Hilda Yulianita, Yulianita Oktarina, Sri http://repository.usmf.md:80/handle/20.500.12710/33386 2026-06-02T09:00:59Z 2026-01-01T00:00:00Z

Title: Strategies for risk assessment in medication management: a systematic review of their impact on patient safety and operational efficiency Authors: Rahmaddian, Tosi; Huvaid, Sevilla Ukhtil; Hidayat, Hilda; Yulianita, Yulianita; Oktarina, Sri Abstract: Introduction. Medication management is a complex, high-risk component of healthcare and remains vulnerable to errors that might affect patient safety and operational efficiency. This systematic review aimed to evaluate risk assessment strategies used in medication management and to synthesize evidence regarding their impact on patient safety and operational performance. Materials and methods. A systematic review was conducted following PRISMA 2020 guidelines. Comprehensive searches of the Scopus and PubMed databases identified peer-reviewed studies published between 2020 and 2025. Using the PICOS framework, eligible studies evaluated risk assessment strategies within medication-use processes and reported patient-related safety and/or efficiency outcomes. Data were analysed through thematic synthesis. Results. Sixteen studies met the inclusion criteria. Proactive risk assessment strategies—notably Failure Mode and Effects Analysis and its variants—were widely implemented across medication-use processes, particularly in high-risk settings. Their use improved the identification and prioritization of medication-related risks, reduced error rates or risk scores, bolstered compliance with safety protocols, and optimized workflow organization and resource allocation. Technology-driven tools further enhanced effectiveness by enabling standardization and continuous monitoring. Conclusions. Structured risk assessment strategies measurably improve patient safety and operational efficiency in medication management. Further longitudinal and comparative research is required to evaluate long-term clinical and economic outcomes.; Introducere. Managementul medicației reprezintă o componentă complexă și cu risc ridicat a sistemului de sănătate, caracterizată prin vulnerabilități persistente, care afectează siguranța pacientului și eficiența operațională. Această revizuire sistematică a examinat strategiile de evaluare a riscurilor utilizate în managementul medicației și a sintetizat dovezile, privind impactul acestora asupra siguranței pacientului și eficienței operaționale. Materiale și metode. A fost realizată o revizuire sistematică conform ghidului PRISMA 2020. Căutările efectuate în bazele de date Scopus și PubMed au identificat studii evaluate de colegi (peer-reviewed), publicate în perioada 2020–2025. Utilizând cadrul PICOS, au fost incluse studiile care au evaluat strategii de evaluare a riscurilor în cadrul proceselor de utilizare a medicamentelor și au raportat rezultate privind siguranța și/ sau eficiența. Datele au fost analizate prin sinteză tematică. Rezultate. Șaisprezece studii au îndeplinit criteriile de includere. Strategiile proactive de evaluare a riscurilor, în special analiza modurilor de defectare și a efectelor acestora (Failure Mode and Effects Analysis – FMEA) și variantele sale, au fost frecvent aplicate în procesele de utilizare a medicamentelor, în special în contexte cu risc înalt. Aplicarea acestora a îmbunătățit identificarea și prioritizarea riscurilor asociate medicației, a redus ratele erorilor sau scorurile de risc, a consolidat conformitatea cu practicile de siguranță și a optimizat organizarea fluxurilor de lucru și utilizarea resurselor. Instrumentele susținute de tehnologie au crescut eficiența prin facilitarea standardizării și monitorizării continue. Concluzii. Strategiile structurate de evaluare a riscurilor contribuie la îmbunătățirea siguranței pacientului și a eficienței operaționale în managementul medicației. Sunt necesare cercetări longitudinale și comparative suplimentare pentru a evalua rezultatele clinice și economice pe termen lung.

2026-01-01T00:00:00Z Villani, Simona http://repository.usmf.md:80/handle/20.500.12710/33385 2026-06-02T07:52:12Z 2026-01-01T00:00:00Z

Title: One health: a strategic imperative for the future of public health Authors: Villani, Simona Abstract: According to the World Health Organization “One Health is an integrated, unifying approach that aims to sustainably balance and optimize the health of people, animals and ecosystems. (...) By linking humans, animals and the environment, One Health can help to address the full spectrum of disease control – from prevention to detection, preparedness, response and management – and contribute to global health security (WHO-One Health)”.It is therefore evident that advancing an integrated and forward-looking vision of health is no longer, but imperative. The One Health approach provides a powerful and necessary framework for addressing the multifaceted nature of today’s public health challenges, from emerging and re-emerging infectious diseases to the far-reaching consequences of environmental change.In this context, One Health & Risk Management stands out as a timely and essential academic platform, committed to fostering interdisciplinary research and meaningful scientific exchange. By bridging disciplines and uniting expertise, this journal plays a critical role in generating robust, evidence-based solutions and in strengthening the connection between research, practice, and policy.From the standpoint of biostatistics and epidemiology, such initiatives are strategically crucial. Rigorous research methodologies grounded in good epidemiological practice, high-quality data, and robust analytical methods constitute the pillars for translating evidence into resilient, responsive, and sustainable health systems. Platforms such as this journal are instrumental in advancing these objectives and in shaping the future of public health.I warmly commend the editorial team for their vision, leadership, and commitment to scientific excellence. I am confident that One Health & Risk Management will establish itself as a leading voice in the global public health community, driving innovation, fostering collaboration, and contributing meaningfully to a healthier and more secure world.

2026-01-01T00:00:00Z CADAR, Dániel http://repository.usmf.md:80/handle/20.500.12710/32511 2026-01-26T11:29:01Z 2026-01-01T00:00:00Z

Title: Metagenomics at the interface of diagnostics and surveillance: a near-term perspective Authors: CADAR, Dániel Abstract: Introduction The global landscape of infectious diseases is undergoing rapid and profound change. Increased human mobility, climate-driven shifts in vector ecology, intensified human-animal-environment interactions, and geopolitical instability have collectively amplified the risk of emerging and re-emerging infectious diseases. At the same time, public health systems are increasingly confronted with pathogens that are unexpected, genetically diverse, or poorly represented in existing diagnostic panels. These developments highlight the growing limitations of exclusively targeted diagnostic approaches and underscore the need for broader, more adaptive tools. In this context, metagenomic sequencing has emerged as a transformative technology. By enabling unbiased detection and genomic characterization of pathogens directly from clinical, environmental, or animal samples, metagenomics offers capabilities that extend far beyond conventional diagnostics. While historically confined to research and outbreak investigations, metagenomics is now approaching a level of maturity that warrants serious consideration for integration into routine diagnostics and risk-oriented surveillance frameworks.

2026-01-01T00:00:00Z